

HAIR DISORDERS

TELOGEN EFFLUVIUM: RESULTS FROM A 4 MONTH, MULTI-CENTRIC, CONTROLLED, RANDOMIZED TRIAL

V. Turlier (1) - M.s. Darde (1) - J. Loustau (1) - L. Liegard (2) - V. Mengeaud (2)

Pierre Fabre Dermo-cosmétique, Skin Research Center, Toulouse, France (1) - Pierre Fabre Dermo-cosmétique, Medical Management Ducray, Lavaur, France (2)

Introduction: Telogen effluvium, a diffuse shedding of telogen hair, occurs about 3 months after a triggering event such as stress, specific drugs, nutritional deprivation...and can induce an impairment of the quality of life.

Objectives: A 4 month, bi-centric, controlled, opened randomized trial was conducted to investigate the efficacy and safety of the RV3466F lotion, developed to reduce hair loss and reactivate hair growth.

Material & Methods: 100 women (19 to 50 years old) with acute telogen effluvium were enrolled in 2 parallel groups (treated/ untreated). The RV3466F lotion was applied thrice a week for 4 months. Both groups used the same neutral shampoo. Measurements such as phototrichogram (PTG), 60 seconds hair count test (60"HC), standardized photographs, questionnaire were performed. Statistical comparisons used pair t-test or Wilcoxon test, and unpaired t-test or Mann-Whitney test depending on the data.

Results: From the PTG results, after 1, 2 and 4 months of use of RV3466F, we observed:

- a significant decrease (p<0.05) in the telogen hair density significantly superior to control (p=0.0465) at M2, and a trend at M1 (p=0.0653).
- a significant increase in the anagen/telogen ratio (A/T) (p<0.001) almost significantly superior to control (p=0.0693) at M1.

From the 60" HC, the number of hairs shed decreased significantly compared to the M1 count (p<0.000) in both groups, that was significantly superior to control (p=0.0392) at M2, and a trend at M4 (p=0.0584).

The global tolerance of the lotion in association with the neutral shampoo was judged as excellent by the dermatologist.

Conclusion: The decrease of the telogen hair density and the number of hairs shed illustrate the anti-hair-loss effect of the RV3466F lotion, significant compared to an untreated group at 2 months. The RV3466F lotion allows the faster resolution of the telogen effluvium, with an excellent dermatological tolerance.





